20587-29-5

Basic information

• Product Name: methyl 4-methyl-2-nitrobenzoate
• Synonyms: methyl 4-methyl-2-nitrobenzoate
• CAS NO: 20587-29-5
• Molecular Weight: 195.175
• Mol File: 20587-29-5.mol

Chemical Properties

• CAS DataBase Reference: methyl 4-methyl-2-nitrobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-methyl-2-nitrobenzoate(20587-29-5)
• EPA Substance Registry System: methyl 4-methyl-2-nitrobenzoate(20587-29-5)

Safety Data

• Hazardous Substances Data: 20587-29-5(Hazardous Substances Data)

Upstream product

• 320740-33-8 methyl 3-bromo-4-methyl-2-nitrobenzoate 
• 67-56-1 methanol 
• 50424-81-2 4-methyl-2-nitro-benzoyl chloride 
• 27329-27-7 4-methyl-2-nitrobenzoic acid 
• 320740-32-7 3-bromo-4-methyl-2-nitrobenzoic acid 
• 7356-52-7 3-acetylamino-4-methyl-2-nitrobenzoic acid 
• 6946-14-1 3-acetylamino-4-methylbenzoic acid 
• 2458-12-0 3-amino-p-toluic acid 
• 74-88-4 methyl iodide 

Downstream Products

• 142051-43-2 4-bromomethyl-2-nitrobenzoic acid methyl ester 
• 20357-22-6 2-nitro-4-methylbenzaldehyde 
• 22996-24-3 (4-methyl 2-nitro-phenyl)-methanol 

Relevant articles and documents

Tricyclic compound as plasma kallikrein inhibitor and application thereof

The invention provides a tricyclic plasma kallikrein inhibitor compound which is novel in structure, good in activity and high in selectivity. The tricyclic plasma kallikrein inhibitor compound can be widely applied to prevention or treatment of diseases related to plasma kallikrein activity.

Discovery and Structure-Activity Relationships of Quinazolinone-2-carboxamide Derivatives as Novel Orally Efficacious Antimalarials

A phenotypic high-throughput screen allowed discovery of quinazolinone-2-carboxamide derivatives as a novel antimalarial scaffold. Structure-activity relationship studies led to identification of a potent inhibitor 19f, 95-fold more potent than the origin

Compound with dual inhibitory activity TDO, IDOO1 and application of compound for treating neurodegenerative disease (by machine translation)

The present invention provides a compound of formula I, or a pharmaceutically acceptable salt thereof, or a solvate thereof, which can selectively inhibit TDO, IDOO1, which has a significant inhibitory effect on TDO and/or IDOO1. In addition, the prepared compound has a remarkable anti-tumor effect, has a certain treatment effect on's disease and's disease, and has a good application prospect in the field of medicine preparation. (by machine translation)

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: I

The synthesis of C2-symmetric and axially chiral compounds for recognition and catalysis

Axially chiral amidines and guanidines, some possessing C2-symmetry, have been targeted as potential chiral catalysts for reactions of α,β-unsaturated carboxylic acids or esters. The key step in each synthesis required the coupling of two sterically demanding aromatic compounds to form atropisomeric biaryl species. (C) 2000 Elsevier Science Ltd.